GIMBE Foundation strongly supports the AllTrials initiative for three reasons. First, 21 years after the birth of the EBM it is now time for a true (and not a selectively published) evidence base to inform all professional, managerial and political decisions. Secondly, the selective or missed publication of trials clearly breaks the pact with participants, that through informed consent accept to join the trial to improve knowledge about treatments’ effects on specific conditions. Last, but not least, under-reporting of research leads to a waste of money, as unpublished results will never lead to public health improvements. By ensuring that all trials will be registered and all results will be published, the investments in clinical research will finally turn into real benefits for citizens’ health.
